Conference Call with Syngene International Management and Analysts on Q1FY26 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Syngene International announced Q1FY26 results Revenue from Operations: Rs 875 crore compared to Rs 790 crore during Q1FY25, change 11%. Revenue: Rs 892 crore compared to Rs 808 crore during Q1FY25, change 10%. EBITDA: Rs 224 crore compared to Rs 188 crore during Q1FY25, change 19%. EBITDA Margin: 23% for Q1FY26. PAT: Rs 87 crore compared to Rs 54 crore during Q1FY25, change 59%. PAT Margin: 7% for Q1FY26. Peter Bains, Managing Director and CEO, Syngene International, said: “We are pleased with the growth performance in the first quarter, which is aligned with our expectations. Continued conversion of pilot programs into longer-term contracts within our Research Services business was the main driver underpinning this momentum. In our Biologics manufacturing division, we have seen good progress with the start of operations at the Unit III facility in Bengaluru and in advancing preparations to commence operations at our Bayview facility in the U.S later this year. We continued to strengthen and expand our scientific platform capabilities, bringing online a state-of-the-art, dedicated peptide laboratory. While we remain mindful of ongoing macroeconomic factors, we maintain a confident outlook.” Deepak Jain, Chief Financial Officer, Syngene International, said: “We are pleased with the growth in revenue from operations of 11% year-on-year. Operating EBITDA margins came at around 24%, driven by both revenue growth and a focus on cost optimization. The current quarter’s PAT includes a tax benefit arising from transfer of gratuity funds to Employee Gratuity Trust. We continue to maintain a robust balance sheet enabling us to invest in technology and capabilities to strengthen our customer offerings. While keeping a close watch on market trends, we remain on course to deliver in line with our stated guidance for the year.” Result PDF
Conference Call with Syngene International Management and Analysts on Q4FY25 & Full Year Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Syngene International announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Quarterly revenue from operations crossed Rs 1,000 crore mark for the first time. Reported revenue from operations was up 11% YoY to Rs 1,018 crore and up 8% sequentially from the prior quarter. Operating EBITDA was up by 8% YoY with operating EBITDA Margin at 34%. Reported profit after tax was Rs 183 crore. FY25 Financial Highlights: Revenue from operations was up 4% to Rs 3,642 crore. Operating EBITDA was up by 3% YoY with operating EBITDA margin at 29%. Reported profit after tax, before exceptional items, was down 8% to Rs 475 crore. Adjusted for one offs and exceptional items, the profit after tax for the full year remained broadly flat with a 1% YoY growth. Peter Bains, Managing Director and CEO, Syngene International, said: “Syngene reported revenue growth of 11% YoY, and 8% sequentially crossing the Rs 1,000 crore in a quarter threshold for the first time. At the EBITDA level growth was 9% YoY reflecting good underlying fundamentals. The highlight of the quarter was the acquisition of a state-of-the-art biologics manufacturing facility in the US, strengthening Syngene’s position in the fast-growing biologics CDMO sector and providing a strategic foothold in the US market. Our biologics CDMO business witnessed robust growth supported by commercial manufacturing alongside new development projects. High conversion of pilot projects into full programs in discovery services supported the growth in our research division. The full year results, led by reported revenue growth of 4%, are in line with our January guidance, reflecting a resilient performance in a challenging year. After a muted first half, driven by a sectoral downturn in US biotech funding, we are encouraged to see a return to growth in the second half of the year. Looking at the year ahead, while the wider global market dynamics remain uncertain, we expect the business momentum to continue with pipeline build in both small and large molecules, supported by new pilot programs and conversion of existing pilots in discovery services. On an underlying basis for fiscal year 2026, we expect revenue growth in the early teens reflecting a broad-based growth across research, development and manufacturing services. Adjusted for inventory balancing in large molecule commercial manufacturing at client level, the reported revenue growth is likely to be at mid-single digit. The mid-term indicators for the CRDMO sector remain positive and I am confident that Syngene’s diverse and well-balanced portfolio across research, development and manufacturing services positions us well to navigate the dynamics and continue our growth story.” Deepak Jain, Chief Financial Officer, Syngene International, said: “Q4 growth was broad based across research, development and manufacturing services, underpinning full year growth of 4% on a reported basis and 2% in constant currency. Operating EBITDA growth came in at 3% maintaining a margin of 29% reflecting a sharp focus on operational efficiencies and cost optimization programs. We continued to make strategic investments to enhance our capabilities and capacities across business while maintaining a strong balance sheet and an improved net cash position. For FY25, the Board of Directors has recommended a final dividend of Rs 1.25 per share, subject to shareholders approval. Looking ahead into the next financial year, we expect the momentum to continue, with reported revenue growth at the mid-single digit level. As we bring the new biologics manufacturing facilities into operations, the additional operating costs and depreciation will impact margins. With this, we expect EBITDA margin to moderate from current levels to the mid-twenties and YoY decline in profit after tax.” Result PDF